Structure Therapeutics Inc.
As of Oct 22, 2026, Structure Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $21.93, 76.6% below its 52-week high and below its 200-day average, which is falling.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is GPCR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
GPCR among Biotechnology246th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …246 | GPCR | Stage 4 · wk 6 | 40 | −39.0% |
Structure Therapeutics: quick answers
What stage is Structure Therapeutics in?
As of Oct 22, 2026, Structure Therapeutics (GPCR) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Structure Therapeutics in an uptrend?
No. Structure Therapeutics is in a Stage 4 downtrend. It trades 56.6% below its 200-day average, which is falling.
How far is Structure Therapeutics from its 52-week high?
Structure Therapeutics closed at $21.93 on Oct 22, 2026, 76.6% below its 52-week high of $93.79. Its 52-week low is $21.08.
How has Structure Therapeutics performed over the past year?
As of Oct 22, 2026, Structure Therapeutics is down 18.5% over the past year and down 67.8% so far in 2026.
Which sector and industry is Structure Therapeutics in?
Structure Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.